How BIA-ALCL Is Staged — The MD Anderson System
BIA-ALCL is staged using the MD Anderson Cancer Center Solid Tumor Staging System for BIA-ALCL — not the traditional Ann Arbor system used for most lymphomas — because BIA-ALCL behaves differently from other lymphomas in its initial localized presentation. The MD Anderson system classifies BIA-ALCL based on how far the disease has spread from its origin in the peri-implant fluid or capsule. Diagnosis is made by ultrasound-guided aspiration of seroma fluid and cytological analysis (finding atypical large lymphoma cells expressing CD30, a cell-surface marker), or by capsule biopsy. The stage at diagnosis drives both treatment decisions and legal compensation value.
Stage IA — Seroma-Confined Disease
Stage IA is the earliest and most favorable stage. Lymphoma cells are found only in the seroma fluid or on the inner surface of the fibrous capsule — they have not penetrated the capsule wall. Treatment: complete en bloc capsulectomy (surgical removal of the implant together with the entire surrounding capsule as one intact specimen). When performed with clean margins (no residual disease), Stage IA is typically curable without chemotherapy. Estimated legal compensation range: $50,000 to $300,000. Despite favorable prognosis, Stage IA patients experienced a cancer diagnosis, underwent major surgery, face ongoing surveillance, and lived with the psychological burden of cancer from an elective or reconstructive device — all of which constitute compensable damages.
Stage IB and Stage II — Capsule and Lymph Node Involvement
Stage IB: lymphoma cells have penetrated through to the outer surface of the fibrous capsule. Treatment continues to center on surgery but with closer margins monitoring and more likely adjuvant chemotherapy. Stage IIA: a single regional lymph node (typically axillary — armpit — lymph node) is involved. Stage IIB: multiple lymph nodes in one region are involved. Stage II treatment: surgery followed by CHOP-based chemotherapy (typically 6 cycles), which substantially increases treatment burden, side effects (nausea, hair loss, fatigue, peripheral neuropathy, increased infection risk), and recovery time. Estimated legal compensation range for Stage IB–IIA: $300,000 to $900,000. Stage IIB: $500,000 to $1,200,000.
Stage III and Stage IV — Advanced and Metastatic Disease
Stage III: disease has invaded adjacent structures — the chest wall, skin, or breast tissue. Treatment requires aggressive multimodal therapy. Stage IV: distant metastases to organs such as the liver, lungs, bone, or central nervous system — the most serious BIA-ALCL stage with the worst prognosis. Stage IV treatment includes intensive chemotherapy, potentially including brentuximab vedotin (anti-CD30 targeted therapy) and autologous stem cell transplant for eligible patients. Prognosis for Stage IV BIA-ALCL is significantly worse than early-stage disease, with 5-year survival rates substantially reduced. Estimated legal compensation range: Stage III — $700,000 to $1,500,000. Stage IV — $1,000,000 to $3,000,000 or more. Wrongful death cases from BIA-ALCL have commanded the highest valuations in comparable medical device MDLs. Stage at diagnosis is documented in pathology reports; an attorney will obtain all relevant records during case evaluation.
Frequently Asked Questions
Related Pages
BIA-ALCL is not breast cancer — it is a T-cell lymphoma of the immune system that develops in the fluid or capsule surrounding Allergan BIOCELL textured implants. It is often curable when caught early, but advanced stages require chemotherapy and carry serious health consequences.
Learn moreThe July 24, 2019 Allergan BIOCELL recall was the largest breast implant recall in FDA history. It covered 33+ product lines after the FDA determined BIOCELL recipients faced a 6x elevated risk of BIA-ALCL lymphoma. French regulators had recalled the same product a year earlier in 2018.
Learn moreBreast implant illness (BII) is a constellation of systemic symptoms — fatigue, brain fog, joint pain, hair loss — reported by implant patients. Unlike BIA-ALCL, BII is not yet a formally recognized diagnosis, but BII plaintiffs with Allergan BIOCELL implants are included in MDL 2921 litigation.
Learn moreThe Allergan Natrelle 410 Highly Cohesive Anatomically Shaped implant was the most widely used recalled product and is at the center of MDL 2921. McGhan textured implants — an earlier Allergan brand — are also covered by the July 2019 recall. If you received either product, you may have a claim.
Learn moreWomen who received Allergan BIOCELL textured implants or tissue expanders as part of post-mastectomy breast reconstruction after breast cancer are a distinct and especially sympathetic plaintiff class in MDL 2921. They fought breast cancer once — and Allergan's recalled product put them at risk of a second cancer.
Learn moreThe FDA does not recommend prophylactic removal of Allergan BIOCELL implants for asymptomatic patients. However, women who chose explantation after the recall may have legal claims for surgery costs. Women with BIA-ALCL symptoms require immediate medical evaluation — not observation.
Learn moreNo global Allergan BIOCELL settlement has been announced as of February 2026. The October 2026 bellwether trial will drive settlement negotiations. Based on comparable medical device MDLs, BIA-ALCL Stage IA cases may settle in the $50,000–$300,000 range; Stage IV cases may command $1,000,000–$3,000,000 or more.
Learn moreThe statute of limitations for Allergan BIOCELL claims is typically 2 to 3 years from discovery — meaning from BIA-ALCL diagnosis, not from implant placement or recall date. Discovery rule protections apply in most states. Consult an attorney immediately — deadlines are strict and MDL tolling is not automatic.
Learn moreYou may qualify if you received Allergan BIOCELL textured implants (for augmentation or reconstruction), were diagnosed with BIA-ALCL, or had your implants removed due to the recall. You do not need a cancer diagnosis to file. Implants already removed do not disqualify you.
Learn moreAllergan Breast Implant Lawsuit Lawsuit
Allergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.
View full case overview